Bio-Techne

TECH · NASDAQ

$72.58+$0.09 (+0.12%)TodayMarket closed ·
Prev close $72.49

News sentiment

Tone of recent coverage

Social media sentiment, last 30 days

Average tone of posts mentioning TECH, from −1 (all negative) to +1 (all positive). Latest day: −0.30 across 58 mentions.

Latest news

  • Press releasePRNewswire

    Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

  • Press releasePRNewswire

    Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

  • Press releasePRNewswire

    Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN

  • Press releasePRNewswire

    Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger - AUUD, TECH, CZR and CBAN

  • Press releasePRNewswire

    Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

  • Press releaseBusiness Wire

    TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Bio-Techne Corrects Dividend Announcement

  • News

    Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate

  • Press releasePRNewswire

    Bio-Techne Releases Fourth Quarter Fiscal 2026 Results

  • Press releasePRNewswire

    Bio-Techne Declares Dividend

  • NewsVandana Singh

    Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover

  • Press releasePRNewswire

    Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

  • Press releasePRNewswire

    Are SYNA, IRDM, TECH, PATK Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH

  • Press releasePRNewswire

    Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?

  • NewsPiero Cingari

    Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today

  • Press releasePRNewswire

    Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releasePRNewswire

    Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

  • NewsAvi Kapoor

    Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday

  • NewsVandana Singh

    Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal

  • Press releaseBusiness Wire

    TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

  • News

    CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing

  • Press releasePRNewswire

    Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

  • News

    'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News

  • News

    Bio‑Techne And Refeyn Launch An Integrated Workflow To Characterize Charge And Size Variants In Bispecific Antibodies And Biosimilars

  • Press releasePRNewswire

    Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

  • News

    Earnings Scheduled For May 6, 2026

  • NewsPiero Cingari

    S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today

  • News

    Bio-Techne Q3 2026 Earnings Call: Complete Transcript

  • Press releasePRNewswire

    Bio-Techne Releases Third Quarter Fiscal 2026 Results

  • Press releasePRNewswire

    Bio-Techne Declares Dividend

  • Press releasePRNewswire

    Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

  • Press releasePRNewswire

    Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity

  • Press releasePRNewswire

    Bio-Techne Declares Dividend

  • Press releasePRNewswire

    Bio-Techne Releases Second Quarter Fiscal 2026 Results

  • News

    Bio-Techne Launches New Synthetic Gel to Improve Stem Cell and Organoid Research

  • Press releasePRNewswire

    Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative

  • Press releasePRNewswire

    Bio-Techne Releases First Quarter Fiscal 2026 Results

  • Press releasePRNewswire

    BIO-TECHNE DECLARES DIVIDEND

  • News

    An Overview of Bio-Techne's Earnings

  • Press releasePRNewswire

    ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.